Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Decision Analysis of Treatment Strategies for Ventilator-Associated Pneumonia

    In late-onset VAP, survival improved and costs decreased using initial coverage with 3 antibiotics. Mini-BAL did not improve survival but decreased costs and antibiotic usage.
  • High FIO2 Deleterious in Acute Asthma

    Adult patients presenting with acute asthma without significant respiratory acidosis who were given 100% oxygen to breathe had slight increases in arterial PCO2 and slight decreases in arterial pH and peak expiratory flow, as compared with patients who received only 28% oxygen.
  • Daily ‘Sedation Vacation’: Long-Term Adverse Effects?

    This single-center study reveals that, compared to continuous sedation, daily sedative interruption is not associated with adverse psychological effects after 6-21 months.
  • Use of Restraining Therapies in the ICU

    A consensus group making recommendations on the use of restraining therapies in the ICU emphasizes the inadequacy of the evidence base in this area and calls for studies to generate better data.
  • Market Updates

    Bypass surgery done on a beating heart is just as effective as the conventional operation performed with a heart-lung machine, and less expensive, according to a study reported last month.
  • Business Developments

    In a move designed to shore up its sagging vascular brachytherapy (VBT) sales, which have been ravaged by the drug-eluting stent (DES) phenomenon, Novoste (Norcross, Georgia) said in an earnings conference call last month that it had signed an agreement with Guidant (Indianapolis, Indiana) to facilitate a transition to Novoste products by existing customers of Guidants vascular brachytherapy system in the U.S. and Canada.
  • Clarification

    A story in the January issue of CDU included an incorrect reference to the InRatio point-of-care tester for prothrombin time as being an i-STAT (East Windsor, New Jersey) product. InRatio is manufactured by HemoSense (Milpitas, California).
  • Report from Europe

    Major progress has been made in the treatment of coronary heart disease in the UK, according to a report issued by Health Secretary John Reid. The report, Winning the War on Heart Disease, said that deaths from cardiovascular disease in the UK fell by more than 23% between the periods 1995-97 and 2000-02.
  • GE Healthcare shines spotlight on its growing presence in cardiology

    At the American College of Cardiology (Bethesda, Maryland) scientific sessions in early March at the Ernest N. Morial Convention Center, the sprawling exhibit floor was, as usual, a bustling center of activity. Perhaps no company embodied the spirit of constant on-the-go activity more than GE Healthcare (Waukesha, Wisconsin), the new umbrella moniker for all of General Electrics (Fairfield, Connecticut) healthcare-related companies.
  • STD Quarterly: HIV is on the rise — Take aim with rapid testing, prevention initiatives

    The most comprehensive analysis of U.S. HIV cases completed to date reveals that new HIV diagnoses in 29 states increased in 2002, according to the Centers for Disease Control and Prevention (CDC).